285 related articles for article (PubMed ID: 25846767)
1. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium).
Karve AM; Seth M; Sharma M; LaLonde T; Dixon S; Wohns D; Gurm HS
Am J Cardiol; 2015 Jun; 115(11):1502-6. PubMed ID: 25846767
[TBL] [Abstract][Full Text] [Related]
2. Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Sukul D; Seth M; Dixon SR; Khandelwal A; LaLonde TA; Gurm HS
J Invasive Cardiol; 2017 Oct; 29(10):340-351. PubMed ID: 28420804
[TBL] [Abstract][Full Text] [Related]
3. Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium).
Song C; Sukul D; Seth M; Dupree JM; Khandelwal A; Dixon SR; Wohns D; LaLonde T; Gurm HS
Am J Cardiol; 2017 Dec; 120(11):1926-1932. PubMed ID: 29025684
[TBL] [Abstract][Full Text] [Related]
4. Contemporary use of prasugrel in clinical practice: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Sandhu A; Seth M; Dixon S; Share D; Wohns D; Lalonde T; Moscucci M; Riba AL; Grossman M; Gurm HS
Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):293-8. PubMed ID: 23674313
[TBL] [Abstract][Full Text] [Related]
5. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
6. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome.
Alexopoulos D; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Angelidis C; Petousis S; Stakos D; Parissis H; Vavouranakis M; Davlouros P; Goudevenos J; Stefanadis C
Am Heart J; 2014 Jan; 167(1):68-76.e2. PubMed ID: 24332144
[TBL] [Abstract][Full Text] [Related]
7. Underutilization of Radial Access in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Howe MJ; Seth M; Riba A; Hanzel G; Zainea M; Gurm HS
Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25922417
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
9. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
Cheng JW
Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
[TBL] [Abstract][Full Text] [Related]
10. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Husted S
Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study.
Alexopoulos D; Moulias A; Koutsogiannis N; Xanthopoulou I; Kakkavas A; Mavronasiou E; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2013 Jun; 6(3):277-83. PubMed ID: 23735473
[TBL] [Abstract][Full Text] [Related]
13. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
[TBL] [Abstract][Full Text] [Related]
14. Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?
DiNicolantonio JJ; Serebruany VL
Int J Cardiol; 2013 May; 165(3):396-7. PubMed ID: 23273339
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Torngren K; Ohman J; Salmi H; Larsson J; Erlinge D
Cardiology; 2013; 124(4):252-8. PubMed ID: 23594617
[TBL] [Abstract][Full Text] [Related]
16. One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel.
Simeone JC; Molife C; Marrett E; Frech-Tamas F; Effron MB; Nordstrom BL; Zhu YE; Keller S; Murphy BR; Nair KV; Vetrovec GW; Page RL; McCollam PL
Am J Cardiovasc Drugs; 2015 Oct; 15(5):337-50. PubMed ID: 26359016
[TBL] [Abstract][Full Text] [Related]
17. Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART).
Sahlén A; Varenhorst C; Lagerqvist B; Renlund H; Wallentin L; James SK; Jernberg T
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):5-12. PubMed ID: 27533056
[TBL] [Abstract][Full Text] [Related]
18. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.
Piccolo R; Di Gioia G; Niglio T; D'Anna C; De Rosa R; Strisciuglio T; Bevilacqua M; Piscione F; Cirillo P; Galasso G
Angiology; 2014 Feb; 65(2):130-6. PubMed ID: 23221279
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Bonello L; Laine M; Kipson N; Mancini J; Helal O; Fromonot J; Gariboldi V; Condo J; Thuny F; Frere C; Camoin-Jau L; Paganelli F; Dignat-George F; Guieu R
J Am Coll Cardiol; 2014 Mar; 63(9):872-7. PubMed ID: 24291273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
